# THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study

Study · id `cardio:ct-nct02732704` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02732704](<https://clinicaltrials.gov/study/NCT02732704>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02732704

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT02732704. Allocation not applicable; no masking; primary purpose treatment. Start 2018-04-20 (actual); primary completion 2022-08-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT02732704, source copy `cardio:ctgov-nct02732704-2022-11-18`, retrieved 2026-10-26)
- Started: 2018-04-20 (actual) (ClinicalTrials.gov record NCT02732704, source copy `cardio:ctgov-nct02732704-2022-11-18`, retrieved 2026-10-26)
- Primary completion: 2022-08-29 (actual) (ClinicalTrials.gov record NCT02732704, source copy `cardio:ctgov-nct02732704-2022-11-18`, retrieved 2026-10-26)
- Completion: 2027-09-29 (anticipated) (ClinicalTrials.gov record NCT02732704, source copy `cardio:ctgov-nct02732704-2022-11-18`, retrieved 2026-10-26)
- Countries: United States; Germany; Netherlands (ClinicalTrials.gov record NCT02732704, source copy `cardio:ctgov-nct02732704-2022-11-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02732704-2022-11-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study
- Condition: Aortic Regurgitation
- Intervention (Device): JenaValve Pericardial TAVR System
- Lead sponsor: JenaValve Technology, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: JenaValve Technology, Inc. (`cardio:org-jenavalve-technology-inc`)

## Provenance

Content hash: 56f97fc2a0b0238d9fd33a7512772d930545d9ca6f40066350af189e84eadd8c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
